Haemonetics Corporation Financial Statements (HAE)
|
|
Report date
|
|
|
25.05.2022 |
31.03.2023 |
22.05.2023 |
31.03.2024 |
20.05.2024 |
|
07.11.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
993.2 |
1 169 |
1 169 |
|
1 309 |
|
1 368 |
Operating Income, bln rub |
|
|
80.8 |
156.0 |
156.0 |
|
164.9 |
|
181.3 |
EBITDA, bln rub |
? |
|
178.5 |
249.3 |
249.3 |
|
262.1 |
|
265.7 |
Net profit, bln rub |
? |
|
43.4 |
115.4 |
115.4 |
|
117.6 |
|
112.9 |
|
OCF, bln rub |
? |
|
172.3 |
273.1 |
273.1 |
|
181.8 |
|
149.6 |
CAPEX, bln rub |
? |
|
96.5 |
110.2 |
110.2 |
|
66.3 |
|
278.3 |
FCF, bln rub |
? |
|
75.8 |
162.9 |
162.9 |
|
115.5 |
|
-128.7 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
|
0.000 |
|
0.000 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
|
0.00% |
|
0 |
|
OPEX, bln rub |
|
|
433.8 |
459.1 |
459.1 |
|
526.7 |
|
526.6 |
Cost of production, bln rub |
|
|
487.7 |
553.6 |
553.6 |
|
632.5 |
|
660.4 |
R&D, bln rub |
|
|
46.8 |
50.1 |
50.1 |
|
54.4 |
|
60.8 |
Interest expenses, bln rub |
|
|
17.1 |
14.6 |
14.6 |
|
13.0 |
|
27.0 |
|
Assets, bln rub |
|
|
1 860 |
1 935 |
1 935 |
2 196 |
2 196 |
|
2 525 |
Net Assets, bln rub |
? |
|
749.4 |
818.0 |
818.0 |
960.0 |
960.0 |
|
878.9 |
Debt, bln rub |
|
|
773.6 |
765.9 |
765.9 |
807.8 |
807.8 |
|
1 225 |
Cash, bln rub |
|
|
259.5 |
284.5 |
284.5 |
178.8 |
178.8 |
|
299.3 |
Net debt, bln rub |
|
|
514.1 |
481.4 |
481.4 |
629.0 |
629.0 |
|
925.7 |
|
Ordinary share price, rub |
|
|
63.9 |
82.8 |
82.8 |
85.4 |
85.4 |
|
85.4 |
Number of ordinary shares, mln |
|
|
51.0 |
0.000 |
50.8 |
|
50.7 |
|
50.9 |
|
Market cap, bln rub |
|
|
3 259 |
0 |
4 202 |
0 |
4 328 |
|
4 345 |
EV, bln rub |
? |
|
3 773 |
481 |
4 684 |
629 |
4 957 |
|
5 270 |
Book value, bln rub |
|
|
-28 |
76 |
76 |
-11 |
-11 |
|
-225 |
|
EPS, rub |
? |
|
0.85 |
|
2.27 |
|
2.32 |
|
2.22 |
FCF/share, rub |
|
|
1.48 |
|
3.21 |
|
2.28 |
|
-2.53 |
BV/share, rub |
|
|
-0.55 |
|
1.50 |
|
-0.22 |
|
-4.42 |
|
EBITDA margin, % |
? |
|
18.0% |
21.3% |
21.3% |
|
20.0% |
|
19.4% |
Net margin, % |
? |
|
4.37% |
9.87% |
9.87% |
|
8.98% |
|
8.25% |
FCF yield, % |
? |
|
2.32% |
0.00% |
3.88% |
0.00% |
2.67% |
|
-2.96% |
ROE, % |
? |
|
5.79% |
14.1% |
14.1% |
0.00% |
12.2% |
|
12.9% |
ROA, % |
? |
|
2.33% |
5.96% |
5.96% |
0.00% |
5.35% |
|
4.47% |
|
P/E |
? |
|
75.1 |
0.00 |
36.4 |
|
36.8 |
|
38.5 |
P/FCF |
|
|
43.0 |
0.00 |
25.8 |
|
37.5 |
|
-33.7 |
P/S |
? |
|
3.28 |
0.00 |
3.60 |
|
3.31 |
|
3.18 |
P/BV |
? |
|
-115.9 |
0.00 |
55.3 |
0.00 |
-385.0 |
|
-19.3 |
EV/EBITDA |
? |
|
21.1 |
1.93 |
18.8 |
|
18.9 |
|
19.8 |
Debt/EBITDA |
|
|
2.88 |
1.93 |
1.93 |
|
2.40 |
|
3.48 |
|
R&D/CAPEX, % |
|
|
48.5% |
45.5% |
45.5% |
|
82.1% |
|
21.9% |
|
CAPEX/Revenue, % |
|
|
9.72% |
9.43% |
9.43% |
|
5.06% |
|
20.3% |
|
Haemonetics Corporation shareholders |